binimetinib
Amoy Diagnostics, Pierre Fabre Collaborate to Develop CDx in China
The companion diagnostic kits will support marketing authorization applications for Pfizer's Braftovi and Mektovi.
Foundation Medicine Test Nabs FDA Approval as CDx for BRAF Inhibitor Therapeutics for Melanoma
FoundationOneCDx will also automatically be a companion diagnostic for future BRAF inhibitors approved by the FDA that target specific BRAF mutations.
Qiagen Inks Master CDx Collaboration With Array BioPharma
One of the first projects between the firms will be to develop and commercialize a companion diagnostic for the MEK inhibitor binimetinib in NRAS-mutant melanoma.